Vanta Bioscience Reports Significant Losses for FY2025 Amid Revenue Decline
Vanta Bioscience Limited, a preclinical contract research organization, reported a substantial net loss for FY2025. Standalone net loss was Rs 265.95 lakh, compared to a profit of Rs 5.11 lakh in the previous year. Revenue from operations declined by 86.80% to Rs 112.74 lakh. Consolidated results showed a net loss of Rs 477.49 lakh, with revenue falling by 79.80% to Rs 196.36 lakh. The company faced operational challenges, including delays in consolidating financial results due to late receipt of accounts from an associate company. Despite financial difficulties, total assets increased by 2.52% to Rs 52.90 crore, while current liabilities rose by 39.22% to Rs 14.20 crore.
*this image is generated using AI for illustrative purposes only.
Vanta Bioscience Limited , a full-service preclinical contract research organization, has reported a substantial net loss for the financial year ended March 31, 2025, according to the company's latest financial results approved by its Board of Directors.
Standalone Performance
On a standalone basis, Vanta Bioscience recorded a net loss of Rs 265.95 lakh for FY2025, a stark contrast to the profit of Rs 5.11 lakh reported in the previous fiscal year. The company's revenue from operations saw a significant decline, dropping to Rs 112.74 lakh from Rs 855.79 lakh in the previous year, representing a decrease of about 86.80%.
Consolidated Results
The consolidated financial picture showed an even more pronounced downturn. The company's net loss widened to Rs 477.49 lakh from Rs 231.59 lakh in the previous year. Consolidated revenue also experienced a sharp decline, falling to Rs 196.36 lakh from Rs 972.29 lakh, marking a decrease of approximately 79.80%.
Operational Challenges
Vanta Bioscience faced operational hurdles during the fiscal year, particularly in consolidating its financial results. The company reported delays in receiving accounts from its associate company, which led to a postponement in preparing the consolidated results within the prescribed timelines.
Subsidiary Performance
The consolidated results include the performance of two subsidiaries:
- Vanta Clinical Research Limited
- CEBIS India Limited
However, specific details about the individual performance of these subsidiaries were not provided in the financial statement.
Audit Opinion
The statutory auditors, M/s Mathesh & Ramana, provided an unmodified and unqualified opinion on both the standalone and consolidated financial results for FY2025, indicating that the financial statements present a fair view of the company's financial position.
Balance Sheet Highlights
The company's balance sheet as of March 31, 2025, reveals some interesting trends:
| Item | Value (Rs crore) | Change from Previous Year |
|---|---|---|
| Total assets | 52.90 | +2.52% |
| Current assets | 12.00 | +8.11% |
| Fixed assets | 37.90 | +1.34% |
| Current liabilities | 14.20 | +39.22% |
| Shareholders' capital | 19.80 | +0.51% |
Looking Ahead
While the financial results for FY2025 present significant challenges for Vanta Bioscience, the company's ability to maintain its asset base and the unqualified audit opinion suggest that it is navigating through a difficult period. The substantial revenue decline across both standalone and consolidated operations indicates that the company may need to reassess its strategies and market positioning to reverse this trend and return to profitability.
Historical Stock Returns for Vanta Bioscience
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.98% | +3.28% | -0.70% | -3.81% | -49.47% | -85.65% |
16
